Abstract. The effect of desglycinamide9-[Arg8]-vasopressin (DGAVP) on memory processes was studied in
Animal studies have revealed that [Arg8]-vasopressin (AVP) plays a physiological role in memory processes (De Wied et al. 1975; van Wimersma Greidanus et al. 1975b ; Van Ree et al. 1978; Bohus et al. 1978) . Evidence that the memory stimulating effects of AVP are independent of its classical endocrine actions comes from studies with analo¬ gues of the hormone. Desglycinamide9-[Lys8]-vasopressin (DGLVP) and desglycinamide'-fArg8]-vasopressin (DGAVP) , which are practically devoid of pressor and antidiuretic activity (De Wied et al. 1972) , are practically as effective as vasopressin in facilitating memory processes in experimental ani¬ mals (De Wied 1976) .
Recent observations suggest that AVP may also be involved in human memory processes. AVP and related peptides improve memory functions in healthy subjects (Laczi et al. 1982a ; Legros et al. 1978;  Legros & Gilot 1979) , in diabetes insipidus (DI) patients (Laczi et al. 1982a; Gilot et al. 1980) , in depressed patients (Weingartner et al. 1981 ) and in patients suffering from some but not all amne¬ stic syndromes (Drago et (DDAVP) were used in near¬ ly all these studies. We observed however that DGAVP improved memory processes in healthy subjects and in DI patients (Laczi et al. 1982b (Squire 1982; Victor et al. 1971 
Discussion
The main finding of the present study is that intranasal treatment with DGAVP for 7 days did short-term and long-term memories were inferior to those observed in healthy subjects in a previous study (Laczi et al. 1982a (Squire 1982 
